Showing results (1-10 of 25) with videos related to
Sort By:
Pageof 3
Bulletin Du Cancer|September 28, 2020
[ALL in adult patients: Contribution and limits of pediatric management]Florence Rabian, Nicolas BoisselCurrent Hematologic Malignancy Reports|November 25, 2019
Towards a Personalized Treatment of Patients with Chronic Myeloid LeukemiaFlorence Rabian, Etienne Lengline, Delphine ReaClinical Kidney Journal|June 25, 2024
Acute kidney injury after CAR-T cell therapy: exploring clinical patterns, management, and outcomesMaud Vincendeau, Adrien Joseph, Catherine Thieblemont, et al.Bulletin Du Cancer|September 20, 2025
[Choice of bridging therapy prior to reinjection of autologous CAR-T cells in patients aged 0-25 years treated for B-ALL (SFGM-TC)]Cécile Pochon, Florence Rabian, Eolia Brissot, et al.Annals of Hematology|February 11, 2023
Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysisMarco Cerrano, Sylvie Chevret, Emmanuel Raffoux, et al.Plos One|July 7, 2022
Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complicationsSofiane Fodil, Sylvie Chevret, Camille Rouzaud, et al.Bulletin Du Cancer|June 18, 2026
[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)]Manon Delafoy, Marie Vincenti, Aphaia Roussel, et al.Open Forum Infectious Diseases|August 26, 2024
Epidemiology, Clinical Manifestations, Treatment, and Outcome of Mucormycosis: A Review of 77 Cases From a Single Center in FranceBlandine Denis, Matthieu Resche-Rigon, Emmanuel Raffoux, et al.American Journal of Hematology|December 31, 2013
Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapseSylvain Pilorge, Sophie Rigaudeau, Florence Rabian, et al.Pageof 3